Wegovy pill shows 21.6% weight loss and doubles mobility in early responders, new trial data reveals

Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) demonstrated significant weight loss and mobility improvements in adults with obesity in the phase 3 OASIS 4 trial. Nearly 29% of early responders lost an average of 21.6% body weight by week 64, while even non-early responders achieved meaningful weight loss. Additionally, about 80% of participants with poor physical function nearly doubled their mobility compared to placebo. The pill also showed better weight loss and fewer side effects than competitor orforglipron, reinforcing its efficacy and safety profile. These findings highlight Wegovy's potential as a leading oral obesity treatment with broad health benefits.